2021 IPO

Zymergen Stock

Biotechnology Company

Sign up today and learn more about Zymergen Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

Founded

2013

Notable Investors

Goldman Sachs

Headquarters

Emeryville CA, US

Total Funding

$970M

About Zymergen Stock

Zymergen researches, develops, and manufactures microbes for companies. It develops molecules for agriculture, chemicals, materials, pharmaceuticals, electronics, personal care, and more applications. Zymergen’s platform integrates automation, machine learning, and genomics to navigate the genomic search space. It uses a technology platform to optimize microbial strains that aims to improve economics of in-market products, existing production strains within existing manufacturing processes, and the correlation between the lab and commercial manufacturing. Moreover, Zymergen offers new product development, such as engineering any molecules from any microbes that improves the power of biology to develop novel products.

Jed Dean, Joshua J. Hoffman, and Zachary Serber founded the company in 2013, with headquarters in Emeryville in California and an additional office in Seattle in Washington.

Investors

Funding History

June 2015$36.6M
June 2015$6.6M
October 2016$142M
November 2018$435M
July 2020$350M

Management

Chief Executive Officer

Joshua Hoffman

Chief Technology Officer

Aaron Kimball

Press

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo